# FDA Expands Casgevy CRISPR Gene Therapy Approval to Children Age 2 and Older

> fda · REPORTED · 2026-07-01

On July 1, 2026, the FDA expanded approval of Casgevy (exagamglogene autotemcel) to patients aged two years and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first gene therapy cleared for children as young as two in both conditions and extending eligibility to approximately 5,500 additional children in the United States.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biotechnology company; Casgevy, co-developed with CRISPR Therapeutics, is the world's first approved CRISPR-based gene therapy targeting hemoglobin disorders.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://lifesciencedaily.news/weekly-news-roundup-06-july-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.